This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Basaria, S. Articles by Dobs, A. S. Search for Related Content PubMed PubMed Citation Articles by Basaria, S. Articles by Dobs, A. S. Pubmed/NCBI databases Medline Plus Health Information Anabolic Steroids Coping with Chronic Illness

Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases

The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Address all correspondence and requests for reprints to: Adrian S. Dobs, M.D., M.H.S., 1830 East Monument Street, Suite 328, Johns Hopkins Hospital, Baltimore, Maryland 21287. E-mail: adobs{at}jhmi.edu

Abstract

The purpose of this study was to review the preclinical and clinical literature relevant to the efficacy and safety of anabolic androgen steroid therapy for palliative treatment of severe weight loss associated with chronic diseases. Data sources were published literature identified from the Medline database from January 1966 to December 2000, bibliographic references, and textbooks. Reports from preclinical and clinical trials were selected. Study designs and results were extracted from trial reports. Statistical evaluation or meta-analysis of combined results was not attempted.

Androgenic anabolic steroids (AAS) are widely prescribed for the treatment of male hypogonadism; however, they may play a significant role in the treatment of other conditions as well, such as cachexia associated with human immunodeficiency virus, cancer, burns, renal and hepatic failure, and anemia associated with leukemia or kidney failure. A review of the anabolic effects of androgens and their efficacy in the treatment of these conditions is provided. In addition, the numerous and sometimes serious side effects that have been known to occur with androgen use are reviewed.

Although the threat of various side effects is present, AAS therapy appears to have a favorable anabolic effect on patients with chronic diseases and muscle catabolism. We recommend that AAS can be used for the treatment of patients with acquired immunodeficiency syndrome wasting and in severely catabolic patients with severe burns. Preliminary data in renal failure-associated wasting are also positive. Advantages and disadvantages should be weighed carefully when comparing AAS therapy to other weight-gaining measures. Although a conservative approach to the use of AAS in patients with chronic diseases is still recommended, the utility of AAS therapy in the attenuation of severe weight loss associated with disease states such as cancer, postoperative recovery, and wasting due to pulmonary and hepatic disease should be more thoroughly investigated.

This article has been cited by other articles:

				S. Basaria Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth J Androl, September 1, 2008; 29(5): 534 - 539. [Abstract] [Full Text] [PDF]

				S. Shahani, M. Braga-Basaria, and S. Basaria Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2042 - 2049. [Abstract] [Full Text] [PDF]

				H. Rashid, S. Ormerod, and E. Day Anabolic androgenic steroids: what the psychiatrist needs to know Advan. Psychiatr. Treat., May 1, 2007; 13(3): 203 - 211. [Abstract] [Full Text] [PDF]

				C Saudan, N Baume, N Robinson, L Avois, P Mangin, and M Saugy Testosterone and doping control Br. J. Sports Med., July 1, 2006; 40(suppl_1): i21 - i24. [Abstract] [Full Text] [PDF]

				B. L. Jones, P. J. Whiting, and L. P. Henderson Mechanisms of anabolic androgenic steroid inhibition of mammalian {varepsilon}-subunit-containing GABAA receptors J. Physiol., June 15, 2006; 573(3): 571 - 593. [Abstract] [Full Text] [PDF]

				R. C.W. Hall, R. C.W. Hall, and M. J. Chapman Psychiatric Complications of Anabolic Steroid Abuse Psychosomatics, August 1, 2005; 46(4): 285 - 290. [Abstract] [Full Text] [PDF]

				P. Y. Takahashi, P. Y. Liu, P. D. Roebuck, A. Iranmanesh, and J. D. Veldhuis Graded Inhibition of Pulsatile Luteinizing Hormone Secretion by a Selective Gonadotropin-Releasing Hormone (GnRH)-Receptor Antagonist in Healthy Men: Evidence That Age Attenuates Hypothalamic GnRH Outflow J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2768 - 2774. [Abstract] [Full Text] [PDF]

				S. Vlahopoulos, W. E. Zimmer, G. Jenster, N. S. Belaguli, S. P. Balk, A. O. Brinkmann, R. B. Lanz, V. C. Zoumpourlis, and R. J. Schwartz Recruitment of the Androgen Receptor via Serum Response Factor Facilitates Expression of a Myogenic Gene J. Biol. Chem., March 4, 2005; 280(9): 7786 - 7792. [Abstract] [Full Text] [PDF]

				G. J. Kunz, K. O. Klein, R. D. Clemons, M. E. Gottschalk, and K. L. Jones Virilization of Young Children After Topical Androgen Use by Their Parents Pediatrics, July 1, 2004; 114(1): 282 - 284. [Abstract] [Full Text] [PDF]

				N. Baume, L. Avois, C. Schweizer, C. Cardis, J. Dvorak, M. Cauderay, P. Mangin, and M. Saugy [13C]Nandrolone Excretion in Trained Athletes: Interindividual Variability in Metabolism Clin. Chem., February 1, 2004; 50(2): 355 - 364. [Abstract] [Full Text] [PDF]

				A.M.W.J. Schols Nutritional and metabolic modulation in chronic obstructive pulmonary disease management Eur. Respir. J., November 2, 2003; 22(46_suppl): 81s - 86s. [Abstract] [Full Text] [PDF]

				M. Nahrendorf, S. Frantz, K. Hu, C. von zur Muhlen, M. Tomaszewski, H. Scheuermann, R. Kaiser, V. Jazbutyte, S. Beer, W. Bauer, et al. Effect of testosterone on post-myocardial infarction remodeling and function Cardiovasc Res, February 1, 2003; 57(2): 370 - 378. [Abstract] [Full Text] [PDF]